| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|
| Net cash provided by (used in) investing activities | 31,255 | 18,850 | 3,892 |
| Proceeds from exercise of stock options | 115 | 115 | 115 |
| Net cash provided by financing activities | 115 | 115 | 115 |
| Net change in cash and cash equivalents | -16,880 | -14,808 | -12,053 |
| Cash and cash equivalents at beginning of period | 20,549 | - | - |
| Cash and cash equivalents at end of period | 3,669 | - | - |
Eledon Pharmaceuticals, Inc. (ELDN)
Eledon Pharmaceuticals, Inc. (ELDN)